Prophylactic adnexectomy in BRCA1 and BRCA2 gene mutation carriers (а review of literature)
https://doi.org/10.17650/1994-4098-2014-0-1-69-73
Abstract
The development of genetics in the study of predisposition to malignancies, to ovarian and breast cancers in particular, as well as the experi- ence of prophylactic surgery to reduce the risks of these diseases have permitted prophylactic bilateral tube ovariectomy to be used as a main technique in BRCA1 and BRCА2 gene mutation carriers. The purpose of this investigation is to demonstrate key studies in this area.
About the Authors
T. A. Shendrikova
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
K. P. Laktionov
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. I. Vasilenko
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2010 г. М., 2012. 307 с.
2. Портной С.М., Любченко Л.Н., Блохин С.Н. и др. Профилактика BRCA-ассоциированных рака молочной железы и рака яичников. Обзор литературы и собственные данные. Онкогинекология 2012;(1):68–72.
3. Powell C.B., Swisher E.M., Cass I. et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013;129(2):364–71.
4. National Breast and Ovarian Cancer Centre (NBOCC) (2011) Familial Risk Assessment – Breast and Ovarian Cancer (FRABOC). http://www.nbocc.org.au/fraboc/.
5. Manchanda R., Abdelraheim A., Johnson М. et al. Outcome of risk-reducing salpingo- oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 2011;118(7):814–24.
6. Timothy R. Rebbeck, Ph.D., Henry T. et al. Prophylactic оophorectomy in сarriers
7. of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346(21):1616–22.
8. Finch A.P., Lubinski J., Møller P. et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol 2014 [Epub ahead of print].
9. Kauff N.D., Domchek S.M., Friebe T.M. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26(8):1331–7.
10. Dietl J. Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet 2014;289(2):241–6.
11. Reade C.J., McVey R.M., Tone A.A. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can 2014;36(2):133–40.
12. Tone A.A., Salvador S., Finlayson S.J. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012;10(5):296–306.
13. Levanon K., Crum C., Drapkin R. New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. J Clin Oncol 2008;26(32):5284–93.
14. Mingels M.J., Roelofsen T., van der Laak J.A. et al. Tubal epithelial lesions in salpingooophorectomy specimens of BRCA-mutation carriers and controls. Ginecol Onkol 2012;127(1):88–93.
15. Любченко Л.Н. Наследственный рак молочной железы и/или яичников: ДНК- диагностика, индивидуальный прогноз, лечение и профилактика. Автореф. дисс. ... д-ра мед. наук. М., 2009. 50 с.
16. Salhab M., Bismohun S., Mokbel K. Risk- reducing strategies for women carrying BRCA1/2 mutations with o focus on prophylactic surgery. BMC Womens
17. Health 2010;10:28.
Review
For citations:
Shendrikova T.A., Laktionov K.P., Vasilenko A.I. Prophylactic adnexectomy in BRCA1 and BRCA2 gene mutation carriers (а review of literature). Tumors of female reproductive system. 2014;(1):69-73. (In Russ.) https://doi.org/10.17650/1994-4098-2014-0-1-69-73
Views:
929
Email this article 